NASDAQ:COCH
Envoy Medical, Inc.
Envoy Medical, Inc.'s revenue grew 7.1% in fiscal 2025 to $241,000 while operating margin fell to −9240.7%, its lowest in 4 years. Free cash flow was −$18.4M, −7626.6% of revenue, and the diluted share count rose 23.8%.Summary generated from Envoy Medical, Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$241,000
Revenue growth+7.1%
Revenue, 5-yr CAGRn/a
Gross margin−262.7%
Operating margin−9240.7%
Net margin−9857.3%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$18.4M
FCF margin−7626.6%
Share count change+23.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 0 | 0 | 0 | 0 |
| Operating income | −5 | −9 | −18 | −19 | −22 |
| Net income | −0 | −16 | −30 | −21 | −24 |
| Free cash flow | n/a | −9 | −17 | −19 | −18 |
Recent filings
- 8-KOther events
Oct 7, 2026 - DEF 14AProxy statement
Aug 31, 2026 - 8-KDirector or officer change
Aug 27, 2026 - 4Insider transaction report
Aug 26, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KTermination of a material agreement
Jun 30, 2026 - 8-KDirector or officer change
Jun 25, 2026